Dexcom Inc
NASDAQ:DXCM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akron PAO
LSE:AKRN
|
RU |
|
Tubacex SA
MAD:TUB
|
ES |
|
Choice Hotels International Inc
NYSE:CHH
|
US |
|
Midea Group Co Ltd
SZSE:000333
|
CN |
|
G
|
G Enone Energy Co Ltd
KOSDAQ:270520
|
KR |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
25.4B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
180.7B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
127.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
101.1B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.4B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.4B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.5B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.2B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Dexcom Inc
Glance View
Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Dexcom Inc is 62.1%, which is below its 3-year median of 62.5%.
Over the last 3 years, Dexcom Inc’s Gross Margin has decreased from 65.2% to 62.1%. During this period, it reached a low of 60% on Jun 30, 2025 and a high of 65.2% on Dec 31, 2022.